Show simple item record

dc.contributor.authorBallester-Clau, Raquel
dc.contributor.authorTorres Vicente, Gisela
dc.contributor.authorVoltà-Pardo, Tania
dc.contributor.authorLópez-Barroso, Laura
dc.contributor.authorCucala-Ramos, Mercedes
dc.contributor.authorReñé Espinet, Josep M.
dc.contributor.authorPlanella de Rubinat, Montse
dc.date.accessioned2019-02-18T09:37:25Z
dc.date.available2019-02-18T09:37:25Z
dc.date.issued2019
dc.identifier.issn0954-691X
dc.identifier.urihttp://hdl.handle.net/10459.1/65747
dc.description.abstractObjective The aim of this study was to assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) following hospitalization for acute gastrointestinal bleeding (AGIB) in the context of a restrictive transfusion strategy. Patients and methods A retrospective single-center study analyzed patients with AGIB (excluding AGIB secondary to portal hypertension) administered a single FCM dose with or without blood transfusion. Results Eighty-six episodes in 84 patients were analyzed. Seventy-nine patients had upper AGIB. Nineteen episodes were associated with hemodynamic instability. FCM was administered during hospitalization as a single dose of 1000mg iron in 84/86 episodes and as a single dose of 500mg iron in two episodes, with blood transfusion in 60/86 (69.8%) episodes. The mean hemoglobin (Hb) was 9.0g/dl at admission, 7.6g/dl at the lowest in-hospital value, 9.4g/dl at discharge, and 12.7g/dl at followup (mean: 55 days postdischarge) (P<0.001 for follow-up vs. all other timepoints). The lowest mean in-hospital Hb value was 7.2 and 8.8g/dl, respectively, in patients with transfusion+FCM versus FCMalone; the mean Hb was 12.4 versus 13.7g/dl at followup. In patients administered FCM alone, the mean Hb at follow-up in the subpopulations aged older than or equal to 75 years (n=33), Charlson comorbidity index of at least 3 (n=48), and Hb of up to 10g/dl at admission (n=47) were 12.6, 13.1, and 13.3g/dl, respectively. No adverse effects were detected. Conclusion Treatment with FCM for AGIB is associated with a good erythropoietic response and anemia correction after hospitalization, even in severe episodes or when transfusion is needed. FCM is safe and well tolerated, and may support a restrictive transfusion policy. Eur J Gastroenterol Hepatol 31:116–122ca_ES
dc.description.sponsorshipData analysis and medical writing support from a freelance medical writer (C. Dunstall) were funded by Vifor Pharma, Glattbrugg, Switzerland.ca_ES
dc.language.isoengca_ES
dc.publisherLippincott, Williams & Wilkinsca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1097/MEG.0000000000001282ca_ES
dc.relation.ispartofEuropean Journal of Gastroenterology and Hepatology, 2019, vol. 31, núm. 1, p. 116-122ca_ES
dc.rightscc-by-nc-nd (c) Raquel Ballester et al., 2019ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleClinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleedingca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1097/MEG.0000000000001282


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by-nc-nd (c) Raquel Ballester et al., 2019
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Raquel Ballester et al., 2019